ALXN News and Press, Alexion Pharmaceuticals Inc. From 11/22/19

Alexion Pharmaceuticals (NASDAQ: ALXN ) says Japan's Ministry of Health, Labour and Welfare has approved the extension of the current marketing authorization of Soliris (eculizumab) for the prevention of relapse in patients with NMOSD. More news on: Alexion Pharmaceuticals, Inc., Heal...

- SOLIRIS ® (eculizumab) is the first and only approved medication for NMOSD in Japan - - 98% of adult anti-aquaporin-4 (AQP4) antibody-positive patients treated with SOLIRIS were relapse free compared to 63% receiving placebo at 48 weeks - Alexion Pharmaceuticals, Inc. (N...

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the 2019 Stifel Healthcare Conference in New York, NY on Tuesday, November 19th, 2019 at 8:35 a.m. ET. An audio webcast of the presentation will be available live. You can access the webcast at: http://...

Alexion Pharmaceuticals (NASDAQ: ALXN ) initiated with Buy rating and $125 (15% upside) price target at SunTrust. More news on: Alexion Pharmaceuticals, Inc., Amgen Inc., Arcus Biosciences, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

BioCryst (NASDAQ: BCRX ) has reported promising results from the phase 1 trial which is currently being carried out on BCX9930 to inhibit the alternative pathway of complement system. The trial is being carried out on 72 healthy volunteers and has resulted in a continuous suppression of mo...

Biotech Pulse Biotech finally has a pulse. The improving appetite for risk has resuscitated the moribund biotechs and pharma (biopharma) groups. The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have begun their advance from their year-to-date lows recorded earlier in Octo...

- Accepted abstracts include presentations of ULTOMIRIS ® (ravulizumab-cwvz) Phase 3 PNH data through 52 weeks - - ULTOMIRIS is the first and only long-acting C5 complement inhibitor, now available in the U.S. for the treatment of PNH and aHUS - Alexion Pharmaceuticals, Inc...

Source: ClearBridge Investments Editor's Note : The summary bullets for this article were chosen by Seeking Read more ...

Source : ClearBridge Investments Editor's Note: The summary bullets for this article were chosen by Seeking Read more ...

Read more ...